Abstract Number: 1165 • 2012 ACR/ARHP Annual Meeting
Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Background/Purpose: The advent of new therapies for juvenile idiopathic arthritis (JIA), particularly the introduction of biologic medications, has increased considerably the potential for treatment benefit,…Abstract Number: 1166 • 2012 ACR/ARHP Annual Meeting
Clinical and Therapeutic Features of 312 Patients with Macrophage Activation Syndrome Enrolled in a Multinational Survey
Background/Purpose: A multinational collaborative effort aimed to develop a new set of criteria for macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA) has…Abstract Number: 1167 • 2012 ACR/ARHP Annual Meeting
Golimumab in 25 Young Adults Affected by Juvenile Idiopathic ARTHRITIS NON Responders to OTHER Biological Agents: Preliminary DATA
Background/Purpose: Biological agents licensed in JIA have demonstrated a favourable benefit-to-risk profile. Nevertheless, intolerance, loss and lack of efficacy or adverse events have led to…Abstract Number: 1168 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis of Early Biologic Treatment in Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: The optimal timing of high cost biologic therapies in the treatment of polyarticular juvenile idiopathic arthritis (JIA) is uncertain. We evaluated the economic and…Abstract Number: 1169 • 2012 ACR/ARHP Annual Meeting
Obstetrical Complications in Women with Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile idiopathic arthritis (JIA) most often affects women before childbearing age. Patients with JIA and their parents often ask about the potential impact of…Abstract Number: 1170 • 2012 ACR/ARHP Annual Meeting
Folate Usage in Methotrexate -Treated Juvenile Idiopathic Arthritis Patients Is Inconsistent and Highly Variable
Background/Purpose: Low-dose weekly methotrexate (MTX) is the first-choice second-line drug in the treatment of juvenile idiopathic arthritis (JIA). Folate (as either Folic acid (FA) or…Abstract Number: 1171 • 2012 ACR/ARHP Annual Meeting
Validation of BASDAI and BASFI in Children with Spondyloarthritis
Background/Purpose: Juvenile-onset Spondyloarthritis (JSpAs), referred to as Enthesitis-Related Arthritis (ERA) subtype under the International League of Associations for Rheumatology (ILAR) classification is characterized by arthritis…Abstract Number: 1172 • 2012 ACR/ARHP Annual Meeting
Delineating the Role of Multiple Corticosteroid Joint Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era
Background/Purpose: Intra-articular corticosteroid injection (IACI) therapy in juvenile idiopathic arthritis (JIA) is generally considered for the treatment of children with arthritis in a small number…Abstract Number: 1173 • 2012 ACR/ARHP Annual Meeting
Targeting Remission in Juvenile Idiopathic Arthritis in Routine Clinical Care: Experience in 175 Newly-Diagnosed Patients
Background/Purpose: The recent advances in the management of juvenile idiopathic arthritis (JIA) have increased considerably the potential to achieve disease remission or, at least, low…Abstract Number: 1174 • 2012 ACR/ARHP Annual Meeting
Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study
Background/Purpose: biologic agents have revolutionized the treatment of Juvenile Idiopathic Arthritis (JIA) and other conditions due to their high efficacy and safety. However, with the…Abstract Number: 1175 • 2012 ACR/ARHP Annual Meeting
Decreased Frequency of Th17 Cells in Early Rheumatoid Arthritis
Background/Purpose: Our objective was to examine the frequency and phenotype of Th17 cells in the peripheral blood of early RA (eRA) patients. Methods: CD4+ T…Abstract Number: 1136 • 2012 ACR/ARHP Annual Meeting
Aesthetic Dissatisfaction in Hand Osteoarthritis Patients, Its Impact and Risk Factors
Background/Purpose: Hand osteoarthritis (HOA) leads to aesthetic damage and is rarely studied. We aim to investigate in HOA patients the prevalence of dissatisfaction with the…Abstract Number: 1137 • 2012 ACR/ARHP Annual Meeting
Clinimetric Properties of a New Outcome Measure:the Hand-Osteoarthritis Aesthetic Damage Index
Background/Purpose: The 2006 OARSI Guidelines for hand OA clinical trials, recognised the potential value of an aesthetic damage assessment, but acknowledged the absence of any…Abstract Number: 1138 • 2012 ACR/ARHP Annual Meeting
Nonpharmacologic and Pharmacologic Therapy Utilization by Primary Care Providers for Hand Osteoarthritis-Comparative Review by Electronic Health Record Data Mining and in-Home Visit Verification
Background/Purpose: To compare current utilization of usual nonpharmacologic (NP) and pharmacologic (P) therapies for hand osteoarthritis (OA) by primary care providers (PCPs) and patients (Pts)…Abstract Number: 1139 • 2012 ACR/ARHP Annual Meeting
Inhaled Nitrous Oxide Facilitates Access to Intra-Articular Corticosteroid Injections in Children with Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood affecting 1 in 1000 children. Medical management for arthritis often includes intra-articular…